<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fibrinogen, concentrate from human plasma: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fibrinogen, concentrate from human plasma: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fibrinogen, concentrate from human plasma: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9082" href="/d/html/9082.html" rel="external">see "Fibrinogen, concentrate from human plasma: Drug information"</a> and <a class="drug drug_patient" data-topicid="102901" href="/d/html/102901.html" rel="external">see "Fibrinogen, concentrate from human plasma: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F6862568"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Fibryga;</li>
<li>RiaSTAP</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52912018"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Fibryga;</li>
<li>RiaSTAP</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F10575786"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Blood Product Derivative</span></li></ul></div>
<div class="block dop drugH1Div" id="F6864405"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing must be individualized for each patient based on the extent of bleeding, laboratory values, clinical condition of the patient, and target fibrinogen concentration.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="82e516aa-9b98-4d56-bf20-c138b0511f77">Congenital fibrinogen deficiency; treatment of acute bleeding</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Congenital fibrinogen deficiency; treatment of acute bleeding:</b>
<b>Note: </b>The recommended target fibrinogen concentration is 100 mg/dL for minor bleeding and 150 mg/dL for major bleeding.</p>
<p style="text-indent:-2em;margin-left:4em;">Initial dose:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>When baseline fibrinogen concentration is known:</i></p>
<p style="text-indent:-2em;margin-left:8em;">RiaSTAP: Infants, Children, and Adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15919240','lexi-content-ref-19804533','lexi-content-ref-RiaSTAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15919240','lexi-content-ref-19804533','lexi-content-ref-RiaSTAP.1'])">Ref</a></span>): IV:</p>
<p style="text-indent:-2em;margin-left:10em;">Dose (mg/kg) = [Target fibrinogen concentration (mg/dL) – measured fibrinogen concentration (mg/dL)] <b>divided by 1.7</b> (mg/dL per mg/kg body weight)</p>
<p style="text-indent:-2em;margin-left:8em;">Fibryga:</p>
<p style="text-indent:-2em;margin-left:10em;">Children &lt;12 years: IV:</p>
<p style="text-indent:-2em;margin-left:12em;">Dose (mg/kg) = [Target fibrinogen concentration (mg/dL) – measured fibrinogen concentration (mg/dL)] <b>divided by</b>
<b>1.4</b> (mg/dL per mg/kg body weight)</p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥12 years and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:12em;">Dose (mg/kg) = [Target fibrinogen concentration (mg/dL) – measured fibrinogen concentration (mg/dL)] <b>divided by 1.8</b> (mg/dL per mg/kg body weight)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>When baseline fibrinogen level is not known:</i> Fibryga, RiaSTAP: Infants, Children, and Adolescents: IV: 70 mg/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Repeat doses: Adjust dose based on laboratory values and condition of patient. Administer additional doses if the fibrinogen concentration falls below 80 mg/dL for minor bleeding and below 130 mg/dL for major bleeding until hemostasis is achieved.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51112123"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51112124"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F6864406"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9082" href="/d/html/9082.html" rel="external">see "Fibrinogen, concentrate from human plasma: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6b93336e-2bb1-4ce9-ba32-8c0ce0bc167a">Congenital fibrinogen deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Congenital fibrinogen deficiency:</b> IV: <b>Note:</b> Maintain a target fibrinogen level of 100 mg/dL for minor bleeding and 150 mg/dL for major bleeding.</p>
<p style="text-indent:-2em;margin-left:4em;">When baseline fibrinogen level is known:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Fibryga:</b> Dose (mg/kg) = [Target level (mg/dL) - measured level (mg/dL)] <b>divided by</b> 1.8 (mg/dL per mg/kg body weight)</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>RiaSTAP:</b> Dose (mg/kg) = [Target level (mg/dL) - measured level (mg/dL)] <b>divided by</b> 1.7 (mg/dL per mg/kg body weight)</p>
<p style="text-indent:-2em;margin-left:4em;">When baseline fibrinogen level is not known: 70 mg/kg</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990552"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987893"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F6864345"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (&gt;5%), vomiting (&gt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic: Thrombocythemia (&gt;5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (&gt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (&gt;1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Ischemia (digital foot), peripheral thrombophlebitis (upper limbs), portal vein thrombosis (following splenectomy)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin, pruritus</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, arterial thrombosis, deep vein thrombosis, pulmonary embolism, thromboembolism, thrombosis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea</p></div>
<div class="block coi drugH1Div" id="F6864322"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Severe, immediate hypersensitivity reactions, including anaphylaxis to fibrinogen, human plasma-derived products, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F6864343"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions (eg, hives, generalized urticaria, chest tightness, wheezing, hypotension, anaphylaxis) may occur. In the event of hypersensitivity reactions, treatment should be discontinued immediately.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombotic events: Thrombosis may occur spontaneously in patients with congenital fibrinogen deficiency with or without fibrinogen replacement therapy. Thromboembolic events have been reported in patients receiving fibrinogen concentrate. Consider potential risk of thrombosis with use; monitor for signs and symptoms of thrombosis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease (eg, viruses and theoretically the Creutzfeldt-Jakob disease [CJD]). Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not indicated for the treatment of dysfibrinogenemia.</p></div>
<div class="block dosfc drugH1Div" id="F50906636"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Strengths expressed with approximate values. Consult individual vial labels for exact potency within each vial.</p></div>
<div class="block foc drugH1Div" id="F6864450"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, powder for reconstitution:</p>
<p style="text-indent:-2em;margin-left:4em;">Fibryga: ~1 g [exact potency labeled on vial]</p>
<p style="text-indent:-2em;margin-left:4em;">RiaSTAP: 900-1300 mg [contains albumin (human); exact potency labeled on vial]</p></div>
<div class="block geq drugH1Div" id="F6864314"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block dinfoc drugH1Div" id="F54008894"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection, powder for reconstitution:</p>
<p style="text-indent:-2em;margin-left:4em;">Fibryga: ~1 g [exact potency labeled on vial]</p>
<p style="text-indent:-2em;margin-left:4em;">RiaSTAP: 900-1300 mg [contains albumin (human); exact potency labeled on vial]</p></div>
<div class="block admp drugH1Div" id="F52614290"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: For IV administration only. Infuse slowly at ≤5 mL/minute. Solution should be infused at room temperature. Do not administer with other products or IV solutions. Administrations should be completed within 4 hours (Fibryga) or 8 hours (RiaSTAP) after reconstitution.</p></div>
<div class="block adm drugH1Div" id="F6864446"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> For IV administration only; infuse at a rate not exceeding 5 mL/minute. Solution should be infused at room temperature. Do not administer with other products or IV solutions. Administration should be completed within 8 hours (RiaSTAP) or 4 hours (Fibryga) after reconstitution. For RiaSTAP, filter reconstituted solution with a 17-micron filter (not supplied) into an appropriate syringe before administration. For Fibryga, filter reconstituted solution with the supplied 17-micron particle filter into an appropriate syringe before administration.</p></div>
<div class="block sts drugH1Div" id="F6864359"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Fibryga: Store intact vials at 2°C to 25°C (36°F to 77°F) in original carton; do not freeze. Protect from light. Discard partially used vials. Reconstituted solution should be used within 4 hours; do not refrigerate or freeze.</p>
<p style="text-indent:-2em;margin-left:2em;">RiaSTAP: Store intact vials at 2°C to 8°C (36°F to 46°F) in original carton; do not freeze. Protect from light. Discard partially used vials. Reconstituted solution is stable for 8 hours when stored at 20°C to 25°C (68°F to 77°F).</p></div>
<div class="block usep drugH1Div" id="F53570340"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency including afibrinogenemia and hypofibrinogenemia (Fibryga: FDA approved in children and adults; RiaSTAP: FDA approved in pediatric patients [age not specified] and adults).</p></div>
<div class="block cyt drugH1Div" id="F13299332"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6871911"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F54124412"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients with congenital fibrinogen deficiency may have an increased risk of bleeding, thrombosis, and pregnancy loss; replacement therapy may be initiated prior to conception (RCOG [Pavord 2017]).</p></div>
<div class="block pri drugH1Div" id="F6864319"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Pregnant patients with congenital fibrinogen deficiency may have an increased risk of bleeding, thrombosis, and pregnancy loss; therefore, close surveillance is recommended. Maternal fibrinogen concentrations increase during pregnancy but do not protect against potential complications. Prophylaxis throughout pregnancy may be needed and higher doses may be required as pregnancy progresses. Plasma derived fibrinogen concentrate may be used for treatment or prevention of bleeding in patients with severe deficiency (RCOG [Pavord 2017]).</p></div>
<div class="block mopp drugH1Div" id="F53570339"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Fibrinogen level; signs/symptoms of hypersensitivity and thrombosis  </p></div>
<div class="block rerp drugH1Div" id="F53569725"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Normal fibrinogen concentrations: 200 to 450 mg/dL</p>
<p style="text-indent:-2em;margin-left:2em;">Congenital fibrinogen deficiency: Target fibrinogen concentrations for acute bleeding:</p>
<p style="text-indent:-2em;margin-left:4em;">Minor bleeding: 100 mg/dL</p>
<p style="text-indent:-2em;margin-left:4em;">Major bleeding: 150 mg/dL</p></div>
<div class="block pha drugH1Div" id="F6864443"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Fibrinogen (coagulation factor I), a protein found in normal plasma, is required to clot blood. Fibrinogen concentrate made from pooled human plasma replaces this protein which is missing or reduced in patients with a congenital fibrinogen deficiency.</p></div>
<div class="block phk drugH1Div" id="F6864361"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>In pediatric patients (12 to 17 years of age) receiving Fibryga, pharmacokinetic values were reported to be similar to adult data.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">Fibryga:</p>
<p style="text-indent:-2em;margin-left:6em;">Patients &lt;6 years of age: 68.6 ± 4.4 mL/kg (range: 63.9 to 72.7 mL/kg).</p>
<p style="text-indent:-2em;margin-left:6em;">Patients 6 to &lt;12 years of age: 67.2 ± 8.2 mL/kg (range: 52.8 to 76.8 mL/kg).</p>
<p style="text-indent:-2em;margin-left:6em;">Patients ≥12 years of age (including adults): 70.2 ± 29.9 mL/kg (range: 36.9 to 149.1 mL/kg).</p>
<p style="text-indent:-2em;margin-left:4em;">RiaSTAP: Patients 8 to 61 years of age: 52.7 ± 7.48 mL/kg (range: 36.22 to 67.67 mL/kg).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Similar to biological fibrinogen.</p>
<p style="text-indent:-2em;margin-left:4em;">Biological fibrinogen: 100 hours (Kamath 2003).</p>
<p style="text-indent:-2em;margin-left:4em;">Fibryga:</p>
<p style="text-indent:-2em;margin-left:6em;">Patients &lt;6 years of age: 56.9 ± 10.8 hours (range: 45.6 to 67 hours).</p>
<p style="text-indent:-2em;margin-left:6em;">Patients 6 to &lt;12 years of age: 66.1 ± 12.1 hours (range: 57.7 to 91.6 hours).</p>
<p style="text-indent:-2em;margin-left:6em;">Patients ≥12 years of age (including adults): 75.9 ± 23.8 hours (range: 40 to 157 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">RiaSTAP:</p>
<p style="text-indent:-2em;margin-left:6em;">Patients &lt;16 years of age: 69.9 ± 8.54 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Patients ≥16 years of age: 82.3 ± 20.04 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion:</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance:</p>
<p style="text-indent:-2em;margin-left:6em;">Fibryga:</p>
<p style="text-indent:-2em;margin-left:8em;">Patients &lt;6 years of age: 0.9 ± 0.1 mL/hour/kg (range: 0.8 to 1 mL/hour/kg).</p>
<p style="text-indent:-2em;margin-left:8em;">Patients 6 to &lt;12 years of age: 0.7 ± 0.1 mL/hour/kg (range: 0.5 to 0.9 mL/hour/kg).</p>
<p style="text-indent:-2em;margin-left:8em;">Patients ≥12 years of age (including adults): 0.7 ± 0.2 mL/hour/kg (range: 0.4 to 1.2 mL/hour/kg).</p>
<p style="text-indent:-2em;margin-left:6em;">RiaSTAP: Patients 8 to 61 years of age: 0.59 ± 0.13 mL/hour/kg (range: 0.45 to 0.86 mL/hour/kg); subgroup analysis showed faster clearance in subjects &lt;16 years of age.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F12992809"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Clottafact | Fibclot | Haemocomplettan p</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Fibrinogeno | Haemocomplettan p</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Fibrinogen human | Fibryga | Haemocomplettan p</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Haemocomplettan p | Riastap</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Fibclot | Fibrinogene | Fibryga | Riastap</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Fibryga | Haemocomplettan</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Fibryga | Haemocomplettan p</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Clottafact | Fibryga | Haemocomplettan p</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Fibrinogen human | Fibroraas | Human Fibrinogen</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Clottafact | Fibryga | Haemocomplettan p</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Fibrinogen immuno | Fibrinogen lidsky | Fibryga</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Fibclot | Fibrinogen | Fibryga | Haemocomplettan hs | Haemocomplettan p</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Fibryga | Haemocomplettan p</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Fibclot | Fibryga | Riastap</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Fibclot | Fibryga | Riastap</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Clottafact | Clottagen | Fibryga | Riastap</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Fibclot | Fibryga | Riastap</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Haemocomplettan p | Riastap</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Fibrinogen human</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Fibrinogen | Fibrinogen human | Fibryga | Haemocomplettan p</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Riastap</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Fibriclotte | Fibryga | Haemocomplettan p | Riastap</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Fibrinogen mitsubishi</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Gcc fibrinogen</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Haemocomplettan</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Fibrema | Fibrinogen | Fibrinogen lidsky | Fibryga</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Fibrinogen | Fibrinogen lidsky | Fibryga</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Clottafact | Riastap</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Fibryga | Haemocomplettan p</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Fibclot | Fibryga | Haemocomplettan p | Riastap</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Fibrinogen | Fibryga | Haemocomplettan hs | Haemocomplettan p | Riastap</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Fibryga | Riastap</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Fibryga | Haemocomplettan</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Fibryga</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Fibryga | Haemocomplettan p</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Haemocomplettan p</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Fibclot | Fibrinogen | Fibryga | Riastap</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Fibryga | Haemocomplettan p</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Haemocomplettan p | Riastap</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Fibryga | Riastap</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Fibrinogen immuno | Haemocomplettan</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Haemocomplettan p</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Fibrinogen | Haemocomplettan p</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Fibryga</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Fibryga</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Fibryga.1">
<a name="Fibryga.1"></a>Fibryga (fibrinogen concentrate [human]) [prescribing information]. Paramus, NJ: Octapharma USA Inc; August 2022.</div>
</li>
<li>
<div class="reference">
                  Fibryga (fibrinogen concentrate [human]) [summary of product characteristics]. Manchester, United Kingdom: Octapharma Ltd; October 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14500858">
<a name="14500858"></a>Kamath S, Lip GY. Fibrinogen: biochemistry, epidemiology and determinants. <i>QJM</i>. 2003;96(10):711-729.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fibrinogen-concentrate-from-human-plasma-pediatric-drug-information/abstract-text/14500858/pubmed" id="14500858" target="_blank">14500858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15919240">
<a name="15919240"></a>Kreuz W, Meili E, Peter-Salonen K, et al. “Efficacy and Tolerability of a Pasteurised Human Fibrinogen Concentrate in Patients With Congenital Fibrinogen Deficiency,” <i>Transfus Apher Sci</i>, 2005, 32(3):247-53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fibrinogen-concentrate-from-human-plasma-pediatric-drug-information/abstract-text/15919240/pubmed" id="15919240" target="_blank">15919240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19804533">
<a name="19804533"></a>Manco-Johnson MJ, Dimichele D, Castaman G, et al. Pharmacokinetics and safety of fibrinogen concentrate. <i>J Thromb Haemost</i>. 2009;7(12):2064-2069.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fibrinogen-concentrate-from-human-plasma-pediatric-drug-information/abstract-text/19804533/pubmed" id="19804533" target="_blank">19804533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28447403">
<a name="28447403"></a>Pavord S, Rayment R, Madan B, et al; for the Royal College of Obstetricians and Gynaecologists. Management of inherited bleeding disorders in pregnancy: Green-top Guideline No. 71 (joint with UKHCDO). <i>BJOG</i>. 2017;124(8):e193–e263. doi: 10.1111/1471-0528.14592.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fibrinogen-concentrate-from-human-plasma-pediatric-drug-information/abstract-text/28447403/pubmed" id="28447403" target="_blank">28447403</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  RiaSTAP (fibrinogen concentrate [human]) [prescribing information]. Kankakee, IL: CSL Behring LLC; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-RiaSTAP.1">
<a name="RiaSTAP.1"></a>RiaSTAP (fibrinogen concentrate [human]) [product monograph]. West Sussex, UK: CSL Behring UK Limited; March 2016</div>
</li></ol></div><div id="topicVersionRevision">Topic 106573 Version 74.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
